Gilead has FDA approval for a twice-yearly PrEP drug, but could proposed cuts to US funding for HIV prevention programmes hinder its take-up?

Gilead Sciences' already dominant position in HIV pre-exposure prophylaxis (PrEP) could be extended if the FDA approves a new twice-yearly product later this year. The US regulator has started a ...

Makkah, June 11, 2024, SPA -- The advanced, multi-story residential towers in Mina represent a unique architectural model that provides high-quality services to pilgrims during the 1445 AH Hajj season ...